GSK3B and neuroblastoma: SITR1 cooperates with the activity regulator AROS to inhibit the acetylation of GSK3β, inactivating GSK3β, which weakens doxorubicin‐mediated apoptosis in neuroblastoma treatment, leading to tumour resistance.72